Clinical Trials
Click below to read more about each of our Clinical Trials to date
MVX0006 Phase I
Immunogenecity and Safety of GBS-NN/NN2 in Older Adults
MVX0004 Phase II
Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women
MVX0003 Phase I
Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine
MVX0005 Phase II
Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV
MVX0002 Phase I
Group B Streptococcus Vaccine in Healthy Females
MVX13211 Phase I
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age
Fischer et al. Vaccine 2021. Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult women.
read more
Pawlowski et al. Cell Rep Med 2022. A group B Streptococcus alpha-like protein subunit vaccine induces functionally active antibodies in humans targeting homotypic and heterotypic strains.
read more
Other
2020
Correlates of Protection
Dangor et al. Vaccine 2023. Association of infant Rib and Alp1 surface protein N-terminal domain immunoglobulin G and invasive Group B Streptococcal disease in young infants.
read more
